Aprepitant Kit
NDC 68001-669
Product Information
Aprepitant is a ANDA-approved product labeled by Bluepoint Laboratories. Aprepitant is used with other medications to help prevent nausea and vomiting caused by cancer drug treatment (chemotherapy). It is supplied as a kit. This product entry covers the primary NDC 68001-669 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
Aprepitant (NDC 68001-668): PINK (C48328 - OPAQUE [CAP])
Aprepitant (NDC 68001-668): WHITE (C48325 - OPAQUE [BODY])
Aprepitant (NDC 68001-668): CAPSULE (C48336)
Aprepitant (NDC 68001-668): 19 MM
G;584 Aprepitant (NDC 68001-668):
G;585 Aprepitant (NDC 68001-668): 1
Code Structure Chart
Product Details
What is NDC 68001-669?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- Aprepitant (NDC 68001-667)
- APREPITANT (UNII: 1NF15YR6UY)
- APREPITANT (UNII: 1NF15YR6UY) (Active Moiety)
- Aprepitant (NDC 68001-668)
- APREPITANT (UNII: 1NF15YR6UY)
- APREPITANT (UNII: 1NF15YR6UY) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- Aprepitant (NDC 68001-667)
- HYDROXYETHYL CELLULOSE (140 MPA.S AT 5%) (UNII: 8136Y38GY5)
- VITAMIN E POLYETHYLENE GLYCOL SUCCINATE (UNII: O03S90U1F2)
- POLOXAMER 407 (UNII: TUF2IVW3M2)
- POVIDONE, UNSPECIFIED (UNII: FZ989GH94E)
- MANNITOL (UNII: 3OWL53L36A)
- WATER (UNII: 059QF0KO0R)
- SODIUM STEARYL FUMARATE (UNII: 7CV7WJK4UI)
- MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- GELATIN, UNSPECIFIED (UNII: 2G86QN327L)
- SODIUM LAURYL SULFATE (UNII: 368GB5141J)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- SHELLAC (UNII: 46N107B71O)
- FERROSOFERRIC OXIDE (UNII: XM0M87F357)
- POTASSIUM HYDROXIDE (UNII: WZH3C48M4T)
- Aprepitant (NDC 68001-668)
- HYDROXYETHYL CELLULOSE (140 MPA.S AT 5%) (UNII: 8136Y38GY5)
- VITAMIN E POLYETHYLENE GLYCOL SUCCINATE (UNII: O03S90U1F2)
- POLOXAMER 407 (UNII: TUF2IVW3M2)
- POVIDONE, UNSPECIFIED (UNII: FZ989GH94E)
- MANNITOL (UNII: 3OWL53L36A)
- WATER (UNII: 059QF0KO0R)
- SODIUM STEARYL FUMARATE (UNII: 7CV7WJK4UI)
- MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- FD&C RED NO. 3 (UNII: PN2ZH5LOQY)
- GELATIN, UNSPECIFIED (UNII: 2G86QN327L)
- SODIUM LAURYL SULFATE (UNII: 368GB5141J)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- SHELLAC (UNII: 46N107B71O)
- FERROSOFERRIC OXIDE (UNII: XM0M87F357)
- POTASSIUM HYDROXIDE (UNII: WZH3C48M4T)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 403810 - aprepitant 80 MG Oral Capsule
- RxCUI: 403811 - aprepitant 125 MG Oral Capsule
- RxCUI: 644088 - aprepitant 40 MG Oral Capsule
- RxCUI: 754508 - {1 (aprepitant 125 MG Oral Capsule) / 2 (aprepitant 80 MG Oral Capsule) } Pack
- RxCUI: 754508 - aprepitant 125 MG (1), 80 MG (2) Oral Capsule 3 Count Pack
* Please review the full disclaimer at the bottom of this page.
Patient Education
Aprepitant
Aprepitant is used with other medications in adults and children 6 months of age and older to prevent nausea and vomiting that may occur after receiving cancer chemotherapy treatment. It is also used with other medications in adults and children 6 months of age and older to prevent delayed nausea and vomiting that may occur several days after receiving certain chemotherapy medications. Aprepitant is not used to treat nausea and vomiting that you already have. Aprepitant is in a class of medications called antiemetics. It works by blocking the action of neurokinin, a natural substance in the brain that causes nausea and vomiting.
[Learn More]
* Please review the full disclaimer at the bottom of this page.